Vermillion holds off delisting with $20.5m from share sales:
This article was originally published in Clinica
Diagnostics specialist Vermillion (formerly Ciphergen Biosystems) has received a timely financial boost - a windfall of $20.5m - from a private placement of approximately 24.4 million shares of common stock. The placement, made with a group of existing and new investors, will be used for general working capital and will be welcome relief to the Fremont, California-based firm, which was issued with a non-compliance letter from Nasdaq indicating a stockholders' equity below $2.5m; a market value of listed securities below $35m; or a net income of $500,000 for the previous fiscal year. Vermillion has until September 14 to regain compliance.
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.